Inactivation of Hypoxanthine Guanine Phosphoribosyltransferase by Guanosine Dialdehyde : An Active Site Directed Inhibitor

  • L. A. Johnson
  • R. B. Gordon
  • B. T. Emmerson
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 122B)


Congenital deficiencies of the enzyme HGPRT are invariably associated with metabolic overproduction of purines, which manifest clinically as hyperuricaemia and gout (1). In cases of severe enzyme deficiency (Lesen Nyhan syndrome), these manifestations are accompanied by a bizarre neurological disorder (2). Production of the enzyme deficiency in laboratory animals would be a considerable experimental advantage in studying these disorders. This might be achieved by the use of active-site directed irreversible inhibitors of the enzyme (3). Although a wide range of substrate analogues have been synthesised, most have exhibited poor binding compared to the substrates. A more successful approach has been the modification of the enzyme reaction product GMP. GMP-dialdehyde, the periodate oxidation product of GMP, has been shown to be a specific irreversible inhibitor of HGPRT in cell extracts but was unable to penetrate the intact cell membrane (4, 5). The experiments reported here show that guanosine dialdehyde (GDA), the periodate oxidation product of guanosine, is also a relatively specific but less potent inhibitor of HGPRT and appears to be able to act intracellularly.


High Protein Concentration Intact Cell Membrane Erythrocyte Hemolysate Congenital Deficiency Lesch Nyhan Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kelley, W.N., Rosenbloom, F.M., Henderson, J.F. and Seegmiller, J.E. (1967). Proc. Nat. Acad, Sci. (Wash) 57:1735.CrossRefGoogle Scholar
  2. 2.
    Lesen, M. and Nyhan, W.L. (1964). Am. J. Med. 36:561–570.CrossRefGoogle Scholar
  3. 3.
    Baker, B.R., “Design of Active-Site-Directed Irreversible Enzyme Inhibitors. The Organic Chemistry of the Active Site”. John Wiley and Sons, New York, 1967.Google Scholar
  4. 4.
    Gutensohn, W. and Huber, M. (1975). Hoppe-Seylers Z. Physiol. Chem. 56:431.CrossRefGoogle Scholar
  5. 5.
    Gutensohn, W. and Jahn, H. (1977). Hoppe-Seylers Z. Physiol. Chem. 358:939.PubMedCrossRefGoogle Scholar
  6. 6.
    Khym, J.X. and Cohn, W.E. (1960). J. Am. Chem. Soc. 82:6380.CrossRefGoogle Scholar
  7. 7.
    Hansske, F. and Cramer, C. (1977). Carbohydr. Res. 54:75.PubMedCrossRefGoogle Scholar
  8. 8.
    Emmerson, B.T., Thompson, C.J. and Wallace, D.C. (1972). Ann. Intern. Med. 76:285.PubMedGoogle Scholar
  9. 9.
    Krenitsky, T.A., Papaioannou, R. and Elion, G.B. (1969). J. Biol. Chem. 244:1263.PubMedGoogle Scholar
  10. 10.
    Henderson, J.F., Brox, L.W., Kelley, W.N., Rosenbloom, F.M. and Seegmiller, J.E. (1968). J. Biol. Chem. 243:2514.PubMedGoogle Scholar
  11. 11.
    Krenitsky, T.A. and Papaioannou, R. (1969). J. Biol. Chem. 244:1271.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1980

Authors and Affiliations

  • L. A. Johnson
    • 1
  • R. B. Gordon
    • 1
  • B. T. Emmerson
    • 1
  1. 1.Department of Medicine, Princess Alexandra HospitalUniversity of QueenslandAustralia

Personalised recommendations